MWP
OCUL icon

MYCIO Wealth Partners’s Ocular Therapeutix OCUL Stock Holding History

MYCIO Wealth Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-267,340
Closed -$1.06M – 270
2019
Q4 		$1.06M Hold
267,340
– – 0.07% 126
2019
Q3 		$813K Buy
+267,340
New +$1.2M 0.06% 133

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYCIO Wealth Partners's OCUL Position: Q1 2020 in Review

MYCIO Wealth Partners sold out of Ocular Therapeutix (OCUL) in Q1 2020, closing a stake of 267,340 shares — an estimated $1.06M sold.

MYCIO Wealth Partners first reported a position in OCUL in Q3 2019 and held it in 2 quarters. The position peaked at $1.06M in Q4 2019. 90 funds tracked by Wall St. Rank hold OCUL as of Q1 2020.

  • MYCIO Wealth Partners reported no remaining Ocular Therapeutix position as of Q1 2020 after selling out during the quarter.
  • MYCIO Wealth Partners sold 267,340 Ocular Therapeutix shares in Q1 2020, an estimated $1.06M.
  • MYCIO Wealth Partners first reported a position in Ocular Therapeutix in Q3 2019 and held it in 2 quarters.
  • MYCIO Wealth Partners's Ocular Therapeutix position peaked at $1.06M in Q4 2019.
  • 90 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2020.

Based on MYCIO Wealth Partners's 13F filing for Q1 2020, filed 14 May 2020.